Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry

Human Pathology

Volumn 39, Issue 5, 2008, Pages 731-739

  Trudel, Dominique ^a   Fradet, Yves ^a   Meyer, François ^a   Harel, François ^a   Têtu, Bernard ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Disease free survival; Immunohistochemistry; MMPs; Neoplasms; Prostate

Indexed keywords

GELATINASE A; MATRIX METALLOPROTEINASE 14; PROSTATE SPECIFIC ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; STROMA CELL;

ADULT; AGED; CANADA; DISEASE-FREE SURVIVAL; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 42649083654     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.09.021     Document Type: Article

References (35)

1. Hsing A.W., Tsao L., and Devesa S.S. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85 (2000) 60-67
2. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 (2002) 161-174
3. Noel A., Albert V., Bajou K., et al. New functions of stromal proteases and their inhibitors in tumor progression. Surg Oncol Clin N Am 10 (2001) 417-432
4. Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin Ther Targets 7 (2003) 385-397
5. Strongin A.Y., Collier I., Bannikov G., Marmer B.L., Grant G.A., and Goldberg G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270 (1995) 5331-5338
6. Trudel D., Fradet Y., Meyer F., Harel F., and Tetu B. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res 63 (2003) 8511-8515
7. Vaillancourt L., Têtu B., Fradet Y., et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol 20 (1996) 86-93
8. Schroder F.H., Hermanek P., Denis L., Fair W.R., Gospodarowicz M.K., and Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate Suppl 4 (1992) 129-138
9. Hsu S.M., Raine L., and Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29 (1981) 577-580
10. Hollander M., and Wolfe D.A. Nonparametric statistical methods (1973), John Wiley & Sons, Inc., New York
11. Boag A.H., and Young I.D. Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. Am J Pathol 144 (1994) 585-591
12. Stearns M., and Stearns M.E. Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol Res 8 (1996) 69-75
13. Stearns M.E., and Stearns M. Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a) expression in human prostate cancer. Oncol Res 8 (1996) 63-67
14. Stearns M.E., and Wang M. Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue. Cancer Res 53 (1993) 878-883
15. Wood M., Fudge K., Mohler J.L., et al. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 15 (1997) 246-258
16. Ross J.S., Kaur P., Sheehan C.E., Fisher H.A., Kaufman Jr. R.A., and Kallakury B.V. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 16 (2003) 198-205
17. Kuniyasu H., Troncoso P., Johnston D., et al. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 6 (2000) 2295-2308
18. Still K., Robson C.N., Autzen P., Robinson M.C., and Hamdy F.C. Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate 42 (2000) 18-25
19. Lichtinghagen R., Musholt P.B., Lein M., et al. Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur Urol 42 (2002) 398-406
20. Upadhyay J., Shekarriz B., Nemeth J.A., et al. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res 5 (1999) 4105-4110
21. Montironi R., Lucarini G., Castaldini C., Galluzzi C.M., Biagini G., and Fabris G. Immunohistochemical evaluation of type IV collagenase (72-kd metalloproteinase) in prostatic intraepithelial neoplasia. Anticancer Res 16 (1996) 2057-2062
22. Varani J., Hattori Y., Dame M.K., et al. Matrix metalloproteinases (MMPs) in fresh human prostate tumour tissue and organ-cultured prostate tissue: levels of collagenolytic and gelatinolytic MMPs are low, variable and different in fresh tissue versus organ-cultured tissue. Br J Cancer 84 (2001) 1076-1083
23. Sakata K., Shigemasa K., Nagai N., and Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 17 (2000) 673-681
24. Nawrocki B., Polette M., Marchand V., et al. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. Int J Cancer 72 (1997) 556-564
25. Polette M., and Birembaut P. Membrane-type metalloproteinases in tumor invasion. Int J Biochem Cell Biol 30 (1998) 1195-1202
26. Bisson C., Blacher S., Polette M., et al. Restricted expression of membrane type 1-matrix metalloproteinase by myofibroblasts adjacent to human breast cancer cells. Int J Cancer 105 (2003) 7-13
27. Toth M., Hernandez-Barrantes S., Osenkowski P., et al. Complex pattern of membrane type 1 matrix metalloproteinase shedding. Regulation by autocatalytic cell surface inactivation of active enzyme. J Biol Chem 277 (2002) 26340-26350
28. Hernandez-Barrantes S., Bernardo M., Toth M., and Fridman R. Regulation of membrane type-matrix metalloproteinases. Semin Cancer Biol 12 (2002) 131-138
29. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17 (2001) 463-516
30. Paterson R.F., Ulbright T.M., MacLennan G.T., et al. Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma. Cancer 98 (2003) 1830-1836
31. Iwata H., Kobayashi S., Iwase H., Masaoka A., Fujimoto N., and Okada Y. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 87 (1996) 602-611
32. Afzal S., Lalani E.N., Poulsom R., et al. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum Pathol 29 (1998) 155-165
33. Baker A.H., Edwards D.R., and Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115 (2002) 3719-3727
34. Mori M., Mimori K., Shiraishi T., et al. Analysis of MT1-MMP and MMP2 expression in human gastric cancers. Int J Cancer 74 (1997) 316-321
35. Chung L.W., Hsieh C.L., Law A., et al. New targets for therapy in prostate cancer: modulation of stromal-epithelial interactions. Urology 62 (2003) 44-54